Dr. Reddy’s Launches Anti-Smoking Drug In U.S. Market
Dr. Reddy’s announced the launch in the U.S. market a tablet for treatment of nicotine dependence as an aid to smoking cessation.
Dr. Reddy's Laboratories Ltd. on Thursday announced the launch in the U.S. market of Bupropion Hydrochloride Extended-Release Tablets, USP (SR), a therapeutically equivalent generic version of Zyban, indicated for treatment of nicotine dependence as an aid to smoking cessation.
According to a release by the drug maker, the generic Zyban has been approved by the U.S. Food and Drug Administration. The Zyban brand and generic had U.S. sales of approximately $5.4 million moving annual turnover for the most recent 12 months ending in June 2019, the company said quoting the market reports.
Dr. Reddy's Bupropion Hydrochloride Extended-Release Tablets, USP (SR) are available as 150 mg dosage strength in bottle count sizes of 60. Zyban tablets are indicated for the treatment of nicotine dependence as an aid to smoking cessation.